A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine

Phase 3 Completed 763 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams\[mg\], 100mg, and 200mg taken daily) compared with placebo in the prevention of migraine.

Timeline

Start: 2001-02
Primary completion: —
Completion: 2002-09

Publications

Results Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004 Apr;61(4):490-5. doi: 10.1001/archneur.61.4.490.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topiramate	Small molecule	50 mg	Oral
Subject	Topiramate	Small molecule	100 mg	Oral
Subject	Topiramate	Small molecule	200 mg	Oral

A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine

Summary

Timeline

Publications

Drugs

Indications